Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

1. Incyte's povorcitinib met primary endpoints in Phase 3 STOP-HS trials. 2. Significant patient response improvements compared to placebo after treatment observed. 3. Safety profile of povorcitinib consistent; no new safety concerns noted. 4. Market reaction: INCY stock dropped 11.90% following results announcement. 5. Efficacy results attract attention for future treatments and potential market impact.